Can I Get a Michigan Medical Marijuana Card for ALS (Lou Gehrig's Disease)?

Yes — als (lou gehrig's disease) qualifies under the Michigan Medical Marihuana Program

Amyotrophic lateral sclerosis (ALS / Lou Gehrig's disease) is a qualifying condition under the Michigan Medical Marihuana Program (MMMA). ALS is a progressive neurodegenerative disease that affects motor neurons, and patients face a complex symptom burden — making any therapy that addresses multiple symptoms simultaneously especially valuable. Medical cannabis is one of few options that can help manage several ALS-related symptoms at once: spasticity, sialorrhea (excessive saliva and drooling), pain, sleep disruption, and reduced appetite.

Common symptoms

• Progressive muscle weakness and wasting
• Spasticity
• Difficulty swallowing or speaking
• Fasciculations (muscle twitches)
• Pain (musculoskeletal and neuropathic)
• Sialorrhea (excessive saliva and drooling)
• Sleep disturbance
• Fatigue
• Mood changes

How medical cannabis may help

Cannabinoids address multiple ALS-related symptoms simultaneously through different mechanisms. THC and CBD reduce spasticity through cannabinoid receptors in the central nervous system. THC reduces sialorrhea (a particularly distressing symptom for many ALS patients) by reducing salivary gland activity. Cannabinoids provide both analgesic and anti-inflammatory effects relevant to the musculoskeletal pain that develops as patients become less mobile. The endocannabinoid system also has theoretical neuroprotective roles in motor-neuron disease that are under active investigation, though current clinical use focuses on symptom management rather than disease modification. Many ALS patients value cannabis specifically because it can replace or reduce reliance on multiple medications — anticholinergics for drooling, baclofen for spasticity, opioids for pain, sleep aids — each with its own side-effect burden.

Evidence base

Patient surveys and case series published in the American Journal of Hospice and Palliative Medicine have reported moderate-to-substantial symptom relief from cannabis use among ALS patients across multiple symptom domains including appetite loss, mood, pain, spasticity, and sialorrhea. While there is no large randomized controlled trial of cannabis specifically for ALS, the symptom-management evidence base for cannabinoids in spasticity (well-established in MS), pain, and chemotherapy-induced symptoms (FDA-approved indications) provides indirect support for the symptom-management approach used in ALS palliative care.

Michigan certification requirements

Documentation of ALS diagnosis from a neurologist or ALS specialty clinic. Coordination with your ALS care team — neurologist, palliative care specialist, speech pathologist, respiratory therapist — is strongly recommended given the complexity of ALS management.